NEWTBVAC
Discovery and preclinical development of new generation tuberculosis vaccines
| Coordinatore | STICHTING TUBERCULOSIS VACCINE INITIATIVE
Organization address
address: Runderweg 6 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 18˙995˙943 € |
| EC contributo | 11˙996˙730 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2014-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING TUBERCULOSIS VACCINE INITIATIVE
Organization address
address: Runderweg 6 contact info |
NL (LELYSTAD) | coordinator | 1˙052˙419.00 |
| 2 |
Department of Health
Organization address
address: Quarry House, Quarry Hill contact info |
UK (Leeds) | participant | 1˙029˙980.00 |
| 3 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 815˙000.00 |
| 4 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 794˙000.00 |
| 5 |
STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Organization address
address: LANGE KLEIWEG 161 contact info |
NL (RIJSWIJK ZH) | participant | 778˙000.00 |
| 6 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 626˙575.00 |
| 7 |
INSTITUT PASTEUR
Organization address
address: RUE DU DOCTEUR ROUX 25-28 contact info |
FR (PARIS CEDEX 15) | participant | 586˙000.00 |
| 8 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 573˙000.00 |
| 9 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 542˙000.00 |
| 10 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | participant | 524˙000.00 |
| 11 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 497˙000.00 |
| 12 |
UNIVERSIDAD DE ZARAGOZA
Organization address
address: CALLE PEDRO CERBUNA 12 contact info |
ES (Zaragoza) | participant | 430˙143.00 |
| 13 |
UNIVERSITAET ULM
Organization address
address: HELMHOLTZSTRASSE 16 contact info |
DE (ULM) | participant | 425˙800.00 |
| 14 |
INSTITUT PASTEUR DE LILLE FONDATION
Organization address
address: 1 Rue du professeur Calmette contact info |
FR (LILLE) | participant | 379˙500.00 |
| 15 |
UNIVERSITE LIBRE DE BRUXELLES
Organization address
address: Avenue Franklin Roosevelt 50 contact info |
BE (BRUXELLES) | participant | 317˙000.00 |
| 16 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 299˙600.00 |
| 17 |
INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL
Organization address
address: Carretera de Canyet s/n contact info |
ES (BADALONA BARCELONA) | participant | 244˙366.00 |
| 18 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 200˙000.00 |
| 19 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 200˙000.00 |
| 20 |
INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE
Organization address
address: Rue Juliette Wytsman 14 contact info |
BE (BRUXELLES) | participant | 199˙800.00 |
| 21 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 188˙000.00 |
| 22 |
ASTON UNIVERSITY
Organization address
address: ASTON TRIANGLE contact info |
UK (BIRMINGHAM) | participant | 185˙000.00 |
| 23 |
UNIVERSITATSKLINIKUM ERLANGEN
Organization address
address: Maximiliansplatz 2 contact info |
DE (ERLANGEN) | participant | 185˙000.00 |
| 24 |
ISTITUTO SUPERIORE DI SANITA
Organization address
address: Viale Regina Elena 299 contact info |
IT (ROMA) | participant | 167˙100.00 |
| 25 |
GlaxoSmithKline Biologicals
Organization address
address: Rue de l'Institut 89 contact info |
BE (Rixensart) | participant | 150˙000.00 |
| 26 |
STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK
Organization address
address: Costerweg 50 contact info |
NL (WAGENINGEN) | participant | 145˙000.00 |
| 27 |
UNIVERSITA DEGLI STUDI DI PALERMO
Organization address
address: PIAZZA MARINA 61 contact info |
IT (PALERMO) | participant | 143˙000.00 |
| 28 |
FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA
Organization address
address: Via Vincenzo Vela 6 contact info |
CH (BELLINZONA) | participant | 141˙948.00 |
| 29 |
Vakzine Projekt Management GmbH
Organization address
address: Mellendorfer Strasse 9 contact info |
DE (Hannover) | participant | 100˙000.00 |
| 30 |
PX'Therapeutics
Organization address
address: "15, rue des Martyrs" contact info |
FR (GRENOBLE) | participant | 50˙000.00 |
| 31 |
"MINISTERIE VAN VOLKSGEZONDHEID, WELZIJN EN SPORT"
Organization address
address: PARNASSUSPLEIN 5 contact info |
NL (DEN HAAG) | participant | 27˙499.00 |
| 32 |
EDUCATIONAL FOUNDATION YONSEI UNIVERSITY
Organization address
address: SEONGSANNO SEODAMEMUN GU 262 contact info |
KR (SEOUL) | participant | 0.00 |
| 33 |
HEALTH PROTECTION AGENCY HPA
Organization address
address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 contact info |
UK (LONDON) | participant | 0.00 |
| 34 |
INSTITUT PASTEUR KOREA
Organization address
address: "HAWOLGOK DONG, SEONGBUK GU 39-1" contact info |
KR (SEOUL) | participant | 0.00 |
| 35 |
INTERNATIONAL VACCINE INSTITUTE
Organization address
address: "San 4-8 Bongcheon-7 dong, Kwanak gu" contact info |
KR (Seoul) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current control measures the Millennium Development Goals (MDGs) set for 2015 may be achieved, reaching these would still leave a million people per year dying from TB. Much more effective measures, particularly more effective vaccines will be essential to reach the target of eliminating TB in 2050. Two successive FP5 and FP6 funded projects, Tuberculosis (TB) Vaccine Cluster (2000-2003) and TBVAC (2004-2008), have in the recent decade made significant contributions to the global TB vaccine pipeline, with four vaccines (out of nine globally) being advanced to clinical stages. Both projects strongly contributed to the strengthening and integration of expertise and led to a European focus of excellence that is unique in the area of TB vaccine development. In order to sustain and accelerate the TB vaccine developments and unique integrated excellence of TBVAC, a specific legal entity was created named TuBerculosis Vaccine Initiative (TBVI). The NEWTBVAC proposal is the FP7 successor of TBVAC, and will be coordinated by TBVI. The proposal has the following objectives : 1) To sustain and innovate the current European pipeline with new vaccine discoveries and advance promising candidates to clinical stages; 2) To design new, second generation vaccines based new prime-boost strategies and/or new (combinations of) promising subunit vaccines, that will impact on reduction of disease in exposed individuals; 3) To sustain and innovate discovery, evaluation and testing of new biomarkers, that will be critically important for future monitoring of clinical trials.'
Introduzione (Teaser)
A large European consortium has joined forces to deliver new vaccine candidates against tuberculosis (TB). The identification of promising vaccination antigens and disease-specific biomarkers could improve the dismal prognosis of TB in the near future.